内脏脂肪的体型指数及其变化可预测保留射血分数的心力衰竭的心血管结局。

IF 4.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Wenlong Xu, Fengling He, Haoxiang Huang, Zhiwen Yang, Zhiwen Xiao, Yilin Zhou, Wei Chen, Jiajun Zhou, Ping Lu, Yusheng Ma, Senlin Huang, Yulin Liao, Jianping Bin, Yanmei Chen
{"title":"内脏脂肪的体型指数及其变化可预测保留射血分数的心力衰竭的心血管结局。","authors":"Wenlong Xu, Fengling He, Haoxiang Huang, Zhiwen Yang, Zhiwen Xiao, Yilin Zhou, Wei Chen, Jiajun Zhou, Ping Lu, Yusheng Ma, Senlin Huang, Yulin Liao, Jianping Bin, Yanmei Chen","doi":"10.1093/ehjqcco/qcaf005","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to investigate the relationship between visceral adipose tissue (VAT), measured using a body shape index (ABSI), and outcomes in patients with heart failure with preserved ejection fraction (HFpEF).</p><p><strong>Methods: </strong>ABSI data and cardiovascular outcomes were obtained from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. ABSI was calculated using waist circumference (WC), body mass index, and height. ABSI values were categorized into tertiles for analysis (≤0.078, 0.078-0.084, and > 0.084).</p><p><strong>Results: </strong>In total, 3 319 patients with HFpEF were enrolled during a mean follow-up period of 3.9 years. ABSI was positively associated with a high risk of cardiovascular events in patients with HFpEF after multivariate adjustment. In the highest tertile, higher risks of all-cause mortality (hazard ratio [HR]: 1.464, 95% confidence interval [CI]: 1.150-1.864), cardiovascular death (HR: 1.685, 95% CI: 1.241-2.289), myocardial infarction (MI) (HR: 1.778, 95% CI: 1.088-2.904), and major adverse cardiovascular events (MACEs) (HR: 1.430, 95% CI: 1.123-1.822]) were noted. Patients with previous or current high ABSI had poorer long-term prognoses, with increased risks of all-cause mortality (HR: 1.635, 95% CI: 1.116-2.396), cardiovascular death (HR: 1.724, 95% CI: 1.071-2.775), MI (HR: 2.021, 95% CI: 0.878-4.653), and MACEs (HR: 1.653, 95% CI: 1.117-2.447).</p><p><strong>Conclusion: </strong>ABSI was independently associated with long-term prognosis in patients with HFpEF, and a history of high ABSI was associated with a poorer prognosis later in life, underscoring the importance of reducing VAT in HFpEF. Trial registration: The trial was registered at ClinicalTrials.gov (NCT00094302).</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A body shape index for visceral fat and its changes predict cardiovascular outcomes of heart failure with preserved ejection fraction.\",\"authors\":\"Wenlong Xu, Fengling He, Haoxiang Huang, Zhiwen Yang, Zhiwen Xiao, Yilin Zhou, Wei Chen, Jiajun Zhou, Ping Lu, Yusheng Ma, Senlin Huang, Yulin Liao, Jianping Bin, Yanmei Chen\",\"doi\":\"10.1093/ehjqcco/qcaf005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>This study aimed to investigate the relationship between visceral adipose tissue (VAT), measured using a body shape index (ABSI), and outcomes in patients with heart failure with preserved ejection fraction (HFpEF).</p><p><strong>Methods: </strong>ABSI data and cardiovascular outcomes were obtained from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. ABSI was calculated using waist circumference (WC), body mass index, and height. ABSI values were categorized into tertiles for analysis (≤0.078, 0.078-0.084, and > 0.084).</p><p><strong>Results: </strong>In total, 3 319 patients with HFpEF were enrolled during a mean follow-up period of 3.9 years. ABSI was positively associated with a high risk of cardiovascular events in patients with HFpEF after multivariate adjustment. In the highest tertile, higher risks of all-cause mortality (hazard ratio [HR]: 1.464, 95% confidence interval [CI]: 1.150-1.864), cardiovascular death (HR: 1.685, 95% CI: 1.241-2.289), myocardial infarction (MI) (HR: 1.778, 95% CI: 1.088-2.904), and major adverse cardiovascular events (MACEs) (HR: 1.430, 95% CI: 1.123-1.822]) were noted. Patients with previous or current high ABSI had poorer long-term prognoses, with increased risks of all-cause mortality (HR: 1.635, 95% CI: 1.116-2.396), cardiovascular death (HR: 1.724, 95% CI: 1.071-2.775), MI (HR: 2.021, 95% CI: 0.878-4.653), and MACEs (HR: 1.653, 95% CI: 1.117-2.447).</p><p><strong>Conclusion: </strong>ABSI was independently associated with long-term prognosis in patients with HFpEF, and a history of high ABSI was associated with a poorer prognosis later in life, underscoring the importance of reducing VAT in HFpEF. Trial registration: The trial was registered at ClinicalTrials.gov (NCT00094302).</p>\",\"PeriodicalId\":11869,\"journal\":{\"name\":\"European Heart Journal - Quality of Care and Clinical Outcomes\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Heart Journal - Quality of Care and Clinical Outcomes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjqcco/qcaf005\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Quality of Care and Clinical Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcaf005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在探讨内脏脂肪组织(VAT)与保留射血分数(HFpEF)心力衰竭患者预后之间的关系,该指标采用体型指数(ABSI)测量。方法:ABSI数据和心血管结果来自醛固酮拮抗剂(TOPCAT)治疗保留心功能心力衰竭的试验。ABSI采用腰围(WC)、体重指数和身高计算。ABSI值按三分位(≤0.078、0.078 ~ 0.084、> 0.084)进行分析。结果:共有3 319例HFpEF患者入组,平均随访时间为3.9年。多因素调整后,ABSI与HFpEF患者心血管事件的高风险呈正相关。在最高的分位数中,全因死亡率(风险比[HR]: 1.464, 95%可信区间[CI]: 1.150-1.864)、心血管死亡(风险比:1.685,95% CI: 1.241-2.289)、心肌梗死(风险比:1.778,95% CI: 1.088-2.904)和主要不良心血管事件(主要心血管事件)(风险比:1.430,95% CI: 1.123-1.822)的风险较高。既往或当前ABSI较高的患者长期预后较差,全因死亡率(HR: 1.635, 95% CI: 1.116-2.396)、心血管死亡(HR: 1.724, 95% CI: 1.071-2.775)、心肌梗死(HR: 2.021, 95% CI: 0.878-4.653)和mace (HR: 1.653, 95% CI: 1.117-2.447)的风险增加。结论:ABSI与HFpEF患者的长期预后独立相关,高ABSI病史与后期预后较差相关,强调了降低HFpEF患者VAT的重要性。试验注册:该试验在ClinicalTrials.gov (NCT00094302)注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A body shape index for visceral fat and its changes predict cardiovascular outcomes of heart failure with preserved ejection fraction.

Aims: This study aimed to investigate the relationship between visceral adipose tissue (VAT), measured using a body shape index (ABSI), and outcomes in patients with heart failure with preserved ejection fraction (HFpEF).

Methods: ABSI data and cardiovascular outcomes were obtained from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. ABSI was calculated using waist circumference (WC), body mass index, and height. ABSI values were categorized into tertiles for analysis (≤0.078, 0.078-0.084, and > 0.084).

Results: In total, 3 319 patients with HFpEF were enrolled during a mean follow-up period of 3.9 years. ABSI was positively associated with a high risk of cardiovascular events in patients with HFpEF after multivariate adjustment. In the highest tertile, higher risks of all-cause mortality (hazard ratio [HR]: 1.464, 95% confidence interval [CI]: 1.150-1.864), cardiovascular death (HR: 1.685, 95% CI: 1.241-2.289), myocardial infarction (MI) (HR: 1.778, 95% CI: 1.088-2.904), and major adverse cardiovascular events (MACEs) (HR: 1.430, 95% CI: 1.123-1.822]) were noted. Patients with previous or current high ABSI had poorer long-term prognoses, with increased risks of all-cause mortality (HR: 1.635, 95% CI: 1.116-2.396), cardiovascular death (HR: 1.724, 95% CI: 1.071-2.775), MI (HR: 2.021, 95% CI: 0.878-4.653), and MACEs (HR: 1.653, 95% CI: 1.117-2.447).

Conclusion: ABSI was independently associated with long-term prognosis in patients with HFpEF, and a history of high ABSI was associated with a poorer prognosis later in life, underscoring the importance of reducing VAT in HFpEF. Trial registration: The trial was registered at ClinicalTrials.gov (NCT00094302).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.40
自引率
3.80%
发文量
76
期刊介绍: European Heart Journal - Quality of Care & Clinical Outcomes is an English language, peer-reviewed journal dedicated to publishing cardiovascular outcomes research. It serves as an official journal of the European Society of Cardiology and maintains a close alliance with the European Heart Health Institute. The journal disseminates original research and topical reviews contributed by health scientists globally, with a focus on the quality of care and its impact on cardiovascular outcomes at the hospital, national, and international levels. It provides a platform for presenting the most outstanding cardiovascular outcomes research to influence cardiovascular public health policy on a global scale. Additionally, the journal aims to motivate young investigators and foster the growth of the outcomes research community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信